CA2651033A1 - Constrained compounds as cgrp-receptor antagonists - Google Patents

Constrained compounds as cgrp-receptor antagonists Download PDF

Info

Publication number
CA2651033A1
CA2651033A1 CA002651033A CA2651033A CA2651033A1 CA 2651033 A1 CA2651033 A1 CA 2651033A1 CA 002651033 A CA002651033 A CA 002651033A CA 2651033 A CA2651033 A CA 2651033A CA 2651033 A1 CA2651033 A1 CA 2651033A1
Authority
CA
Canada
Prior art keywords
oxo
mmol
mixture
indazol
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002651033A
Other languages
English (en)
French (fr)
Inventor
Prasad V. Chaturvedula
Stephen E. Mercer
Haiquan Fang
Xiaojun Han
Guanglin Luo
Gene M. Dubowchik
Graham S. Poindexter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2651033A1 publication Critical patent/CA2651033A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002651033A 2006-05-03 2007-05-02 Constrained compounds as cgrp-receptor antagonists Abandoned CA2651033A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US79740006P 2006-05-03 2006-05-03
US60/797,400 2006-05-03
US11/742,626 2007-05-01
US11/742,626 US7470680B2 (en) 2006-05-03 2007-05-01 Constrained compounds as CGRP-receptor antagonists
PCT/US2007/067998 WO2007131020A2 (en) 2006-05-03 2007-05-02 Constrained compounds as cgrp-receptor antagonists

Publications (1)

Publication Number Publication Date
CA2651033A1 true CA2651033A1 (en) 2007-11-15

Family

ID=38544174

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002651033A Abandoned CA2651033A1 (en) 2006-05-03 2007-05-02 Constrained compounds as cgrp-receptor antagonists

Country Status (14)

Country Link
US (1) US7470680B2 (enExample)
EP (1) EP2013214B1 (enExample)
JP (1) JP2009535429A (enExample)
KR (1) KR20090018930A (enExample)
AR (1) AR060845A1 (enExample)
AU (1) AU2007248038A1 (enExample)
BR (1) BRPI0709759A2 (enExample)
CA (1) CA2651033A1 (enExample)
IL (1) IL195027A0 (enExample)
MX (1) MX2008013760A (enExample)
NO (1) NO20084564L (enExample)
PE (1) PE20080232A1 (enExample)
TW (1) TW200813063A (enExample)
WO (1) WO2007131020A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
CA2672230A1 (en) * 2006-12-20 2008-07-17 Merck & Co., Inc. Benzazepine compounds as cgrp receptor antagonists
JP2011512410A (ja) * 2008-02-19 2011-04-21 メルク・シャープ・エンド・ドーム・コーポレイション イミダゾベンゾアゼピンcgrp受容体アンタゴニスト
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
WO2024220626A1 (en) * 2023-04-20 2024-10-24 Azkarra Therapeutics, Inc. Small molecule modulators of ogg1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1606286B1 (en) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Benodiazepine spirohydantoin cgrp receptor antagonists
US7288559B2 (en) 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
WO2004091514A2 (en) 2003-04-15 2004-10-28 Merck & Co., Inc. Cgrp receptor antagonists
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
EP1641781B1 (en) * 2003-06-26 2013-03-06 Merck Sharp & Dohme Corp. Benzodiazepine CGRP receptor antagonists
US7476665B2 (en) * 2003-06-26 2009-01-13 Merck & Co., Inc. Benzodiazepine CGRP receptor antagonists
CN101124217A (zh) 2004-01-29 2008-02-13 默克公司 Cgrp受体拮抗剂
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
US7659264B2 (en) 2004-10-07 2010-02-09 Merck Sharp & Dohme Corp. CGRP receptor antagonists
EP1802637B1 (en) 2004-10-13 2008-10-15 Merck & Co., Inc. Cgrp receptor antagonists
DE602005027870D1 (de) 2004-10-14 2011-06-16 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
US7745427B2 (en) 2004-10-22 2010-06-29 Merck Sharp & Dohme Corp. CGRP receptor antagonists
US7384931B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384930B2 (en) * 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
EP1856100B1 (en) 2005-01-18 2010-05-05 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
EP1861399B1 (en) 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
CA2615463A1 (en) 2005-07-29 2007-02-08 Merck & Co., Inc. Heterocyclic benzodiazepine cgrp receptor antagonists
CA2672230A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Benzazepine compounds as cgrp receptor antagonists

Also Published As

Publication number Publication date
TW200813063A (en) 2008-03-16
PE20080232A1 (es) 2008-04-11
WO2007131020A3 (en) 2008-01-17
US7470680B2 (en) 2008-12-30
KR20090018930A (ko) 2009-02-24
JP2009535429A (ja) 2009-10-01
NO20084564L (no) 2008-12-02
US20070259851A1 (en) 2007-11-08
WO2007131020A2 (en) 2007-11-15
BRPI0709759A2 (pt) 2011-10-25
AR060845A1 (es) 2008-07-16
IL195027A0 (en) 2009-08-03
EP2013214B1 (en) 2015-06-24
MX2008013760A (es) 2008-11-14
EP2013214A2 (en) 2009-01-14
AU2007248038A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
US7544680B2 (en) Constrained compounds as CGRP-receptor antagonists
AU2019294482B2 (en) Heteroaryl compounds for treating Huntington's disease
KR20250024833A (ko) 테트라하이드로피리도피리미딘 PAN-Kras 억제제
EP1945222B1 (en) Pyrrolo[2,1-f] [1,2,4]-triazin-4-ylamines as igf-1r kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
AU2010306954B2 (en) CGRP receptor antagonists
ES2392779T3 (es) Derivados de piperidina como antagonistas del receptor de CGRP
WO2007130860A2 (en) Constrained compounds as cgrp-receptor antagonists
EP2013214B1 (en) Constrained compounds as cgrp-receptor antagonists
CN121568945A (zh) 用于治疗自身免疫病的大环
TW202345797A (zh) 作為ikzf2降解劑之含雙環雜芳基化合物
EP2013213B1 (en) Constrained compounds as cgrp-receptor antagonists
CN101495480B (zh) 作为降钙素基因相关肽受体拮抗剂的受限化合物
WO2020011921A1 (en) P2x3 receptor antagonists
AU2006245517A1 (en) Quinoline derivatives as neurokinin receptor antagonists
CN121949345A (zh) 杂芳基大环化合物及其制备方法和应用

Legal Events

Date Code Title Description
FZDE Discontinued